Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 18, 2026
Why Is Fabrinet (FN) Stock Down -14.28% Today?

Why Is Fabrinet (FN) Stock Down -14.28% Today?

Key Takeaways

  • Shares of FN dropped 14.28% in early trading Tuesday, falling to about $513 from Monday's close of $598.58.
  • The move followed fiscal fourth-quarter 2026 results that beat on revenue and EPS, but disappointed on margins, free cash flow, and the near-term profit trajectory.
  • Guidance for the fiscal first quarter of 2027 implies a sequential decline in earnings per share, cooling expectations after a more than 80% 12-month rally.
  • A mixed analyst reaction added pressure, including one price-target cut tied to softness in the data-communications segment.
  • Broader weakness in technology and AI-infrastructure names compounded the selling, with the Nasdaq and S&P 500 both lower.
  • Traders are watching whether the stock stabilizes near early-August levels and how optical-networking peers trade into the close.

Opening Summary

Fabrinet (FN), a provider of advanced optical packaging and precision optical, electro-mechanical, and electronic manufacturing services, saw its shares plunge Tuesday in a classic "beat-and-retreat" earnings reaction. As of 9:35 a.m. ET, the stock was trading at $513.11, down $85.47, or 14.28%, from Monday's regular-session close of $598.58. The decline came even though the company reported record quarterly revenue and earnings that exceeded Wall Street forecasts. Investors instead focused on shrinking margins, negative free cash flow, softer data-communications results, and guidance that points to a sequential drop in earnings per share.

Earnings Results and Guidance

Fabrinet (FN) delivered strong headline numbers for its fiscal fourth quarter of 2026. Revenue rose 45% year over year to a record $1.316 billion, above the roughly $1.27 billion consensus. Non-GAAP earnings per share came in at $4.10, exceeding the $3.81 estimate. Data-center revenue climbed 68% year over year and crossed the 50% threshold of total revenue for the first time, reflecting robust demand from AI infrastructure and hyperscale customers.

However, the company's fiscal first-quarter 2027 outlook triggered the selloff. Fabrinet (FN) guided revenue to a midpoint of about $1.4 billion, above consensus, but its EPS range of $4.10 to $4.25 implies a sequential decline from the fourth quarter because of seasonal factors. After a year of relentless momentum, the prospect of near-term earnings stepping back was enough to reset expectations.

Margin, Cash Flow, and Segment Concerns

Beneath the headline beat, investors found reasons for caution. Gross margin narrowed by 30 basis points year over year, while free cash flow swung to negative $37 million as capital spending accelerated on capacity expansions in Thailand and California. Management also flagged uncertainty around Thailand's new top-up tax regime and ongoing component-supply constraints.

Segment results showed an uneven growth picture. Data-communications revenue slipped 1% sequentially to $258 million, extending recent softness, while high-performance computing revenue rose 11% sequentially to $118 million. For a stock priced for flawless execution, that combination of margin pressure and segment-level softness overshadowed the company's record top line.

Analyst Reaction and Valuation Pressure

The market reaction was amplified by a mixed analyst response. B. Riley lowered its price target on FN to $598 from $635 while maintaining a Neutral rating, citing the languishing data-communications business. Barclays and J.P. Morgan raised their targets, but both firms noted concerns about the data-communications and high-performance computing segments.

Valuation also played a role. Fabrinet (FN) entered the report with a more than 80% gain over the prior 12 months and traded at a significant premium to its own historical norms after rallying from a 52-week low of $272.49. That left the shares vulnerable to any sign that earnings, margins, or cash generation could fall short of elevated expectations.

Market Context and Trading Activity

The post-earnings drop was reinforced by a risk-off tone across technology markets. The Nasdaq was down about 1% and the S&P 500 slipped roughly 0.4%, with AI-infrastructure and optical-networking names trading broadly lower. Fabrinet (FN) gapped below Monday's intraday low of $576.50, and the early decline took the stock back toward levels last seen in early August. Trading activity was elevated in the opening minutes of the session, consistent with a heavy post-earnings reaction in a widely followed AI supply-chain name.

What Comes Next for FN

The focus now shifts to whether the optical-networking and AI-infrastructure complex can stabilize. Investors will monitor commentary from hyperscale customers on data-center spending, the ramp of new 800G transceiver programs, progress on capacity expansions in Thailand and California, and any resolution of component-supply and tax-related uncertainties. Risks include the company's customer concentration, potential further margin pressure during the expansion phase, and the broader market's appetite for richly valued technology stocks after the recent rally.

Trending AI Robots

Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, and only the strongest performers are featured in this section. The bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a data-driven way to monitor evolving opportunities across names like FN. Explore the curated list to see which AI trading strategies are currently standing out.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: FN

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


FN in +9.29% Uptrend, advancing for three consecutive days on October 02, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where FN advanced for three days, in 272 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 25, 2026. You may want to consider a long position or call options on FN as a result. In 64 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.

The Moving Average Convergence Divergence (MACD) for FN just turned positive on September 18, 2026. Looking at past instances where FN's MACD turned positive, the stock continued to rise in 35 of 46 cases over the following month. The odds of a continued upward trend are 76%.

FN moved above its 50-day moving average on October 01, 2026 date and that indicates a change from a downward trend to an upward trend.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.

FN broke above its upper Bollinger Band on October 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for FN entered a downward trend on September 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. FN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 49 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 65, placing this stock slightly better than average.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.984) is normal, around the industry mean (5.615). P/E Ratio (31.415) is within average values for comparable stocks, (81.453). Projected Growth (PEG Ratio) (0.770) is also within normal values, averaging (1.658). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (3.067) is also within normal values, averaging (4.796).

The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Corning (NYSE:GLW), Universal Display Corp (NASDAQ:OLED).

Industry description

The Electronic Components industry produces electronic equipment for industries and consumer electronics products, such as mobile devices, televisions, and circuit boards. TE Connectivity Ltd, for example, is a company that designs and manufactures connectivity and sensor products for harsh environments in various industries, such as automotive, industrial equipment, aerospace, and oil & gas. Another major player, Corning Inc., makes advanced optics including end-to-end fiber and wireless solutions for communications networks along with various other technologies catering to industrial and scientific applications.

Market Cap

The average market capitalization across the Electronic Components Industry is 14.08B. The market cap for tickers in the group ranges from 5.86K to 208.67B. APH holds the highest valuation in this group at 208.67B. The lowest valued company is NXOPF at 5.86K.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Components Industry was 3%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was 16%. OPTX experienced the highest price growth at 38%, while MTEK experienced the biggest fall at -26%.

Volume

The average weekly volume growth across all stocks in the Electronic Components Industry was -23%. For the same stocks of the Industry, the average monthly volume growth was -7% and the average quarterly volume growth was -43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 48
Price Growth Rating: 48
SMR Rating: 72
Profit Risk Rating: 65
Seasonality Score: 27 (-100 ... +100)
View a ticker or compare two or three
FN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of precision optical, electro-mechanical and electronic manufacturing services

Industry ElectronicComponents

Industry
Electronic Components
Address
C/o Intertrust Corporate Services (Cayman) Limited
Phone
+1 662 524-9600
Employees
21521
Web
https://www.fabrinet.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.